Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Cash & Equivalents (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Cash & Equivalents over the past 16 years, most recently at $8.3 million for Q2 2025.

  • Quarterly results put Cash & Equivalents at $8.3 million for Q2 2025, down 2.33% from a year ago — trailing twelve months through May 2025 was $8.3 million (down 2.33% YoY), and the annual figure for FY2025 was $8.3 million, down 2.33%.
  • Cash & Equivalents for Q2 2025 was $8.3 million at Lifecore Biomedical, Inc. \De\, up from $5.4 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for LFCR hit a ceiling of $19.1 million in Q2 2023 and a floor of $609000.0 in Q4 2021.
  • Median Cash & Equivalents over the past 5 years was $2.7 million (2022), compared with a mean of $4.9 million.
  • Biggest five-year swings in Cash & Equivalents: tumbled 75.4% in 2021 and later surged 1826.44% in 2023.
  • Lifecore Biomedical, Inc. \De\'s Cash & Equivalents stood at $609000.0 in 2021, then soared by 875.04% to $5.9 million in 2022, then skyrocketed by 221.51% to $19.1 million in 2023, then tumbled by 50.47% to $9.5 million in 2024, then fell by 12.59% to $8.3 million in 2025.
  • The last three reported values for Cash & Equivalents were $8.3 million (Q2 2025), $5.4 million (Q1 2025), and $9.5 million (Q4 2024) per Business Quant data.